Effectiveness of innovator dydrogesterone versus generic dydrogesterone in early pregnancy: a real-world analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252717Keywords:
Early pregnancy, Innovator dydrogesterone, Miscarriage, Generic dydrogesterone, Real-world evidenceAbstract
Background: Miscarriage is the most common complication of early pregnancy. Dydrogesterone, a retro-steroid with high oral bioavailability and receptor selectivity, is widely prescribed to support and maintain pregnancy via its novel immunomodulation mechanism. There is a lack of comparative data on the miscarriage rate for pregnant females prescribed innovator, generic, and no dydrogesterone in early pregnancy. This study aimed to evaluate this comparative rate in real-world settings.
Methods: A real-world, retrospective, observational study was conducted using anonymized and aggregated medical records from January 2017 to October 2024. Early pregnancy females (18-45 years) who consulted gynecologists were included. These were categorized into three arms: innovator dydrogesterone (Arm 1), generic dydrogesterone (Arm 2), and no dydrogesterone (Arm 3). These arms were balanced by propensity score matching (PSM), and miscarriage rates were compared using the Chi-square test.
Results: The incidence of miscarriage was significantly lower in the innovator arm (4.10%) compared to Arm 2 (5.54%, p=0.040) and arm 3 (12.46%, p<0.001). No event of miscarriage was reported among women who switched from generic to innovator dydrogesterone. However, one of the females who shifted from innovator to generic experienced a loss of pregnancy.
Conclusions: Innovator dydrogesterone was associated with the lowest rate of miscarriage compared to generic and no dydrogesterone. This suggests its potential clinical benefits in early pregnancy.
Metrics
References
Al-Alami Z, Abu-Huwaij R, Hamadneh S, Taybeh E. Understanding miscarriage prevalence and risk factors: Insights from women in Jordan. Medicina. 2024;60(7):1044. DOI: https://doi.org/10.3390/medicina60071044
Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658-67. DOI: https://doi.org/10.1016/S0140-6736(21)00682-6
National Family Health Survey (NFHS-5), 2019-21, Government of India, Ministry of Health and Family Welfare. 2022.
Alves C, Jenkins SM, Rapp A. Early pregnancy loss (spontaneous abortion). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
du Fossé NA, van der Hoorn MLP, van Lith JMM, le Cessie S, Lashley EELO. Advanced paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(5):650-69. DOI: https://doi.org/10.1093/humupd/dmaa010
Sonu HS, Das SK, Tony R, Binu VS. Risk and protective factors of miscarriage: Evidence from a nationally representative sample of women in India. J Family Med Prim Care. 2024;13(9):3879-86. DOI: https://doi.org/10.4103/jfmpc.jfmpc_329_24
Improving live birth rates in recurrent pregnancy loss: taking a step ahead in managing RPL. 2024.
Bulletti C, Bulletti FM, Sciorio R, Guido M. Progesterone: The key factor of the beginning of life. Int J Mol Sci. 2022;23(22):14138. DOI: https://doi.org/10.3390/ijms232214138
Raghupathy R, Szekeres-Bartho J. Progesterone: A unique hormone with immunomodulatory roles in pregnancy. Int J Mol Sci. 2022;23(3):1333. DOI: https://doi.org/10.3390/ijms23031333
Bataa M, Abdelmessih E, Hanna F. Exploring progesterone deficiency in first-trimester miscarriage and the impact of hormone therapy on foetal development: A scoping review. Children (Basel). 2024;11(4):422. DOI: https://doi.org/10.3390/children11040422
Manickavasagam M, Vakil A, Singh E, Roy H, Lal N, Patel RG, et al. Real-world evidence of dydrogesterone 20 mg and 30 mg SR usage in pregnancy. Cureus. 2024;16(10):e72016. DOI: https://doi.org/10.7759/cureus.72016
Tetruashvili N, Domar A, Bashiri A. Prevention of pregnancy loss: combining progestogen treatment and psychological support. J Clin Med. 2023;12(5):1827. DOI: https://doi.org/10.3390/jcm12051827
Ingale K, Malhotra N, Deshmukh P, Dhonde D, Mehta S. Practice profile of Indian gynaecologists on the use of micronized progesterone and dydrogesterone in pregnancy and assisted reproductive technology cycles: progress survey. Int J Reprod Contracept Obstet Gynecol. 2024;13(7):1805-11. DOI: https://doi.org/10.18203/2320-1770.ijrcog20241778
Ott J, Egarter C, Aguilera A. Dydrogesterone after 60 years: a glance at the safety profile. Gynecological Endocrinol. 2022;38(4):279-87. DOI: https://doi.org/10.1080/09513590.2021.2016692
Guo H, Lu Q. Efficacy of dydrogesterone on treating recurrent miscarriage and its influence on immune factors: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(10):10971-85. DOI: https://doi.org/10.21037/apm-21-2605
Maladkar MN, Tekchandani CM, Luniya SS. Dydrogesterone update: insights on its therapeutic applications. Int J Reprod Contracept Obstet Gynecol. 2024;13(9):2577-84. DOI: https://doi.org/10.18203/2320-1770.ijrcog20242526
Noh IJ, Gray J, Ball G, Wright Z, Park H. Are all generic drugs created equal? An empirical analysis of generic drug manufacturing location and serious drug adverse events. Prod Oper Manag. 2025;10591478251319691. DOI: https://doi.org/10.1177/10591478251319691
Sharma K, Nair T, Chawla M, Kalra S, Baruah M, Tiwaskar M, et al. Innovator vs. generic: the real mccoy vs. the pretender? J Popul Ther Clin Pharmacol. 2024;31(3):2253-66. DOI: https://doi.org/10.53555/jptcp.v31i3.4806
Tuleu C, Hughes DA, Clapham D, Vallet T, Ruiz F. Acceptability of generic versus innovator oral medicines: not only a matter of taste. Drug Discov Today. 2021;26(2):329-43. DOI: https://doi.org/10.1016/j.drudis.2020.11.008
Kuptarak A, Phupong V. Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-blind, placebo-controlled trial. J Matern Fetal Neonatal Med. 2024;37(1):2333929. DOI: https://doi.org/10.1080/14767058.2024.2333929
Ng KYB, Cherian G, Kermack AJ, Bailey S, Macklon N, Sunkara SK, et al. Systematic review and meta-analysis of female lifestyle factors and risk of recurrent pregnancy loss. Sci Rep. 2021;11(1):7081. DOI: https://doi.org/10.1038/s41598-021-86445-2
Qu P, Yan M, Zhao D, Wang D, Dang S, Shi W, et al. Association between pre-pregnancy body mass index and miscarriage in an assisted reproductive technology population: A 10-year cohort study. Front Endocrinol. 2021;12:646162. DOI: https://doi.org/10.3389/fendo.2021.646162
Taha OT. Assessment of the immunomodulatory role of dydrogesterone in preventing pregnancy loss in threatened abortion. W J Gynecol Women's Health. 2020; 3(3):1-5. DOI: https://doi.org/10.33552/WJGWH.2020.03.000567
Hsu CW, Lee SY, Yang YH, Wang LJ. Brand-name antidepressants outperform their generic counterparts in preventing hospitalization for depression: the real-world evidence from Taiwan. Int J Neuropsychopharmacol. 2020;23(10):653-61. DOI: https://doi.org/10.1093/ijnp/pyaa041
Tank J, Gupte S, Mahapatra PC, Reddy J, Mittal P, Mukhopadhyay AK, et al. Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study. Rev Bras Ginecol Obstet. 2024;46:e-rbgo18. DOI: https://doi.org/10.61622/rbgo/2024AO18
Khanna G, Dabade M, Dutta S, Deshpande N, Mane G, Shah C, et al. Dydrogesterone usage pattern in India: a knowledge, attitude and practice survey among Indian gynaecologists. Int J Reprod Contracept Obstet Gynecol. 2021;10(10):3793. DOI: https://doi.org/10.18203/2320-1770.ijrcog20213839
Downloads
Published
How to Cite
Issue
Section
